

**THE NATIONAL IMMUNISATION ADVISORY COMMITTEE
REVISED TETANUS IMMUNE GLOBULIN RECOMMENDATIONS**

Tetanus Immune Globulin (TIG) is indicated for the post-exposure prophylaxis of tetanus-prone wounds in patients whose tetanus immunisation status is inadequate or unknown, and for the treatment of tetanus.

Tetabulin, the only TIG authorised for use in Ireland, is no longer being manufactured so TIG authorised in any EU country may be used (e.g. Human Tetanus Immunoglobulin BPL or Tetagam CSL Behring).

If TIG is not available

- when a risk assessment suggests that a person requires intramuscular tetanus immunoglobulin (TIG), i.e. prophylaxis of a tetanus prone wound in an unvaccinated or inadequately vaccinated person, human normal immunoglobulin HNIG (Subgam BPL) may be given intramuscularly. The volume of Subgam required to achieve the equivalent of the recommended dose of 250IU of tetanus anti-toxin is approximately 5mls.
- when Tetanus is clinically suspected, intravenous HNIG (Vigam BPL) is advised (based on Public Health England analysis of the anti-tetanus content of Vigam).

Dosage

For individuals less than 50 kg, 5,000 IU or 250mls IV

For individuals over 50 kg, 10,000IU or 500mls IV

References:

Public Health England 2013 Q&A on Tetanus and Human Tetanus Immunoglobulin
http://www.hpa.org.uk/webc/hpawebfile/hpaweb_c/1317131148455

Public Health England 2013 HPA Expert Working Group interim guidance on the use of tetanus immunoglobulin for the treatment of tetanus
http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317138740578

Public Health England 2013 Tetanus Immunoglobulin handbook
http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1194947314087

23 July 2013